2023 World Conference on Lung Cancer (Posters)-P2.31. Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy

P2.31. Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to analyze the real-world treatment patterns and outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received platinum chemotherapy and immunotherapy. Data from the Flatiron Health electronic health record database, which includes information from over 280 cancer clinics, was used.<br /><br />The study involved 1216 patients in the real-world cohort and 746 patients in the clinical trial-eligible cohort. The majority of patients in both cohorts had received 1 or 2 prior lines of therapy before starting non-platinum chemotherapy. The most common treatment sequence observed was platinum chemotherapy followed by immunotherapy or vice versa.<br /><br />Among the real-world cohort, taxane combination therapy was the most frequently used index treatment, followed by taxane monotherapy and non-taxane monotherapy. However, the use of taxane combination therapy decreased with subsequent lines of treatment. Non-taxane monotherapy was the most commonly used treatment after the initial therapy.<br /><br />The median overall survival (OS) was 6.7 months in the real-world cohort and 8.1 months in the clinical trial-eligible cohort. The median time to treatment discontinuation (TTD) was 2.3 months, and the median time to next treatment (TTNT) was 4.5 months in the real-world cohort.<br /><br />In conclusion, the study provides insights into the treatment patterns and outcomes of patients with advanced or metastatic NSCLC who have previously undergone platinum chemotherapy and immunotherapy. The findings highlight the widespread use of taxane-based regimens as initial treatments and the limited survival outcomes in this patient population. Further research, such as ongoing clinical trials, is necessary to identify more effective treatment strategies for these patients. An example of such a trial is the EVOKE-01 trial, which is evaluating sacituzumab govitecan versus docetaxel in NSCLC patients who experienced disease progression after receiving chemo-IO.

Asset Subtitle

Shivani Mhatre

Meta Tag

Speaker Shivani Mhatre

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

advanced non-small cell lung cancer

metastatic NSCLC

platinum chemotherapy

immunotherapy

real-world treatment patterns

treatment outcomes

taxane combination therapy

taxane monotherapy

clinical trial-eligible cohort

overall survival